Terms: = Skin cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
1285 results:
1. A Comparative Analysis of Implant-sparing Plan
Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
[TBL] [Abstract] [Full Text] [Related]
2. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of Social Vulnerabilities of Care and Prognosis in Adult Ocular Melanomas in the US.
Mensah JA; Fei-Zhang DJ; Rossen JL; Rahmani B; Bentrem DJ; Stein JD; French DD
Ann Surg Oncol; 2024 May; 31(5):3302-3313. PubMed ID: 38418655
[TBL] [Abstract] [Full Text] [Related]
4. Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease.
Baumrin E; Shin DB; Mitra N; Pidala J; El Jurdi N; Lee SJ; Loren AW; Gelfand JM
JAMA Dermatol; 2024 Apr; 160(4):393-401. PubMed ID: 38416506
[TBL] [Abstract] [Full Text] [Related]
5. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
[TBL] [Abstract] [Full Text] [Related]
6. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF; Schreibelt G; Bloemendal M; van Willigen WW; Hins-de Bree S; de Goede AL; de Boer AJ; Bos KJH; Duiveman-de Boer T; Olde Nordkamp MAM; van Oorschot TGM; Popelier CJ; Pots JM; Scharenborg NM; van de Rakt MWMM; de Ruiter V; van Meeteren WS; van Rossum MM; Croockewit SJ; Koeneman BJ; Creemers JHA; Wortel IMN; Angerer C; Brüning M; Petry K; Dzionek A; van der Veldt AA; van Grünhagen DJ; Werner JEM; Bonenkamp JJ; Haanen JBAG; Boers-Sonderen MJ; Koornstra RHT; Boomsma MF; Aarntzen EHJ; Gotthardt M; Nagarajah J; de Witte TJM; Figdor CG; de Wilt JHW; Textor J; de Groot JWB; Gerritsen WR; de Vries IJM
Nat Commun; 2024 Feb; 15(1):1632. PubMed ID: 38395969
[TBL] [Abstract] [Full Text] [Related]
7. TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
Colombo I; Koster KL; Holer L; Haefliger S; Rabaglio M; Bastian S; Schwitter M; Eckhardt K; Hayoz S; Mc Laughlin AM; Kloft C; Klose M; Halbherr S; Baumgartner C; Sessa C; Stathis A; Hess D; Joerger M
Eur J Cancer; 2024 Apr; 201():113588. PubMed ID: 38377773
[TBL] [Abstract] [Full Text] [Related]
8. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
[TBL] [Abstract] [Full Text] [Related]
9. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated Thyroid cancer Survivors in the United States.
Tran TV; Schonfeld SJ; Pasqual E; Haymart MR; Morton LM; Kitahara CM
Thyroid; 2024 Feb; 34(2):215-224. PubMed ID: 38149602
[No Abstract] [Full Text] [Related]
10. Association of Geriatric Nutritional Risk Index With Immune Checkpoint Inhibitor treatment Duration and Adverse Events in Lung cancer.
Shimizu A; Fukasawa M; Mitani K; Goto K; Wakamoto A; Hatsuyama T; Hoshi T; Hasegawa I; Sato H
In Vivo; 2024; 38(1):418-424. PubMed ID: 38148096
[TBL] [Abstract] [Full Text] [Related]
11. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
12. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; Fuchß M; Ring N; Stäger R; Zellweger C; Ebel C; Kimeswenger S; Oellinger A; Amaral T; Forschner A; Leiter U; Klumpp B; Hoetzenecker W; Terheyden P; Mangana J; Loquai C; Cozzio A; Garbe C; Meier F; Eigentler TK; Flatz L
Eur J Cancer; 2024 Jan; 196():113425. PubMed ID: 38039778
[TBL] [Abstract] [Full Text] [Related]
13. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
Kähler KC; Debus D; Schley G; Göppner D; Hassel JC; Meier F; Terheyden P; Stadler R; Tüting T; Kaatz M; Hoff NP; Masoudi E; Zdanowicz-Specht A; Nguyen MT; Mohr P
Melanoma Res; 2024 Feb; 34(1):44-53. PubMed ID: 37962220
[TBL] [Abstract] [Full Text] [Related]
14. Multidisciplinary neurofibromatosis conference in the management of patients with neurofibromatosis type 1 and schwannomatosis in a single tertiary care institution.
Debs P; Belzberg A; Blakeley J; Fayad L; Langmead S; Little E; Romo C; Schatz K; Slobogean B; Ahlawat S
Skeletal Radiol; 2024 May; 53(5):909-916. PubMed ID: 37950060
[TBL] [Abstract] [Full Text] [Related]
15. [Rheumatic adverse events due to immune checkpoint inhibitors].
van Binsbergen WH; Heslinga SC; Lems WF; Tsang-A-Sjoe MWP; Labots M; van der Laken J
Ned Tijdschr Geneeskd; 2023 Nov; 167():. PubMed ID: 37930161
[TBL] [Abstract] [Full Text] [Related]
16. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract] [Full Text] [Related]
17. Sotorasib plus Panitumumab in Refractory Colorectal cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract] [Full Text] [Related]
18. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
[TBL] [Abstract] [Full Text] [Related]
19. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Khan SA; Mi X; Xu Y; Blanco LZ; Akasha AM; Pilewskie M; Degnim AC; AlHilli Z; Amin AL; Hwang ES; Guenther JM; Kocherginsky M; Benante K; Zhang S; Helland T; Hustad SS; Gursel DB; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Lee O
JAMA Surg; 2023 Dec; 158(12):1265-1273. PubMed ID: 37870954
[TBL] [Abstract] [Full Text] [Related]
20. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.
Hahn E; Chavira R; Wollenberg L; Tan W; Reddy MB
Clin Transl Sci; 2023 Dec; 16(12):2675-2686. PubMed ID: 37837178
[TBL] [Abstract] [Full Text] [Related]
[Next]
